Circulating Tumor Cells in Gastric Cancer

  • Jie ShenEmail author
  • Lifeng Wang


Historically, tumor tissue has been the major source of material used for cancer biomarker evaluation. However, several situations arise where there is a shortage of tissue needed for such tumor tissue-based detection strategies. First, it may be impossible to obtain tissue from advanced case patients. Tissues from biopsy may not always be enough for gene detection. Second, tumor tissue obtained at the time of the initial diagnosis might not reflect alterations of genetic profile observed at the time of clinical progression, because primary and metastatic tumors from the same person can be diffident at levels of genomic, transcriptomic, and epigenetic. Moreover, chemotherapy or targeted therapy may alter gene expression level itself. In such cases, circulating tumor cells could be a noninvasive and useful tool for tracking changes and providing useful and timely information for determining the best course of treatment. It could also be useful for those who do not have enough tissue for adequate gene detection when neoadjuvant or adjuvant chemotherapy needs to be chosen.


Gastric Cancer Advanced Gastric Cancer Circulate Tumor Cell Immunocompromised Mouse Peripheral Mononuclear Blood 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Joosse SA, Gorges TM, Pantel K. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. 2015;7(1):1–11. doi: 10.15252/emmm.201303698.CrossRefPubMedGoogle Scholar
  2. 2.
    Joosse SA, Pantel K. Biologic challenges in the detection of circulating tumor cells. Cancer Res. 2013;73(1):8–11. doi: 10.1158/0008-5472.CAN-12-3422.CrossRefPubMedGoogle Scholar
  3. 3.
    Mitchell MJ, King MR. Computational and experimental models of cancer cell response to fluid shear stress. Front Oncol. 2013;3:44. doi: 10.3389/fonc.2013.00044.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature. 2004;430(7003):1034–9. doi: 10.1038/nature02765.CrossRefPubMedGoogle Scholar
  5. 5.
    Steinert G, Scholch S, Niemietz T, Iwata N, Garcia SA, Behrens B, et al. Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res. 2014;74(6):1694–704. doi: 10.1158/0008-5472.CAN-13-1885.CrossRefPubMedGoogle Scholar
  6. 6.
    McDonald DM, Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res. 2002;62(18):5381–5.PubMedGoogle Scholar
  7. 7.
    Pantel K, Passlick B, Vogt J, Stosiek P, Angstwurm M, Seen-Hibler R, et al. Reduced expression of plakoglobin indicates an unfavorable prognosis in subsets of patients with non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16(4):1407–13.CrossRefGoogle Scholar
  8. 8.
    Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, et al. Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med. 2012;10:138. doi: 10.1186/1479-5876-10-138.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Lianidou ES, Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem. 2011;57(9):1242–55. doi: 10.1373/clinchem.2011.165068.CrossRefPubMedGoogle Scholar
  10. 10.
    Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol. 2006;33(3 Suppl 9):S9–14. doi: 10.1053/j.seminoncol.2006.03.016.CrossRefPubMedGoogle Scholar
  11. 11.
    de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302–9. doi: 10.1158/1078-0432.CCR-08-0872.CrossRefPubMedGoogle Scholar
  12. 12.
    Dotan E, Alpaugh RK, Ruth K, Negin BP, Denlinger CS, Hall MJ, et al. Prognostic significance of MUC-1 in circulating tumor cells in patients with metastatic pancreatic adenocarcinoma. Pancreas. 2016; doi: 10.1097/MPA.0000000000000619.PubMedGoogle Scholar
  13. 13.
    Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014;15(4):406–14. doi: 10.1016/S1470-2045(14)70069-5.CrossRefPubMedGoogle Scholar
  14. 14.
    Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu SJ, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology. 2013;57(4):1458–68. doi: 10.1002/hep.26151.CrossRefPubMedGoogle Scholar
  15. 15.
    Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R, et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat. 2009;115(3):581–90. doi: 10.1007/s10549-008-0143-x.CrossRefPubMedGoogle Scholar
  16. 16.
    Gasch C, Bauernhofer T, Pichler M, Langer-Freitag S, Reeh M, Seifert AM, et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem. 2013;59(1):252–60. doi: 10.1373/clinchem.2012.188557.CrossRefPubMedGoogle Scholar
  17. 17.
    Deneve E, Riethdorf S, Ramos J, Nocca D, Coffy A, Daures JP, et al. Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem. 2013;59(9):1384–92. doi: 10.1373/clinchem.2013.202846.
  18. 18.
    Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450(7173):1235–9. doi: 10.1038/nature06385.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Harb W, Fan A, Tran T, Danila DC, Keys D, Schwartz M, et al. Mutational analysis of circulating tumor cells using a novel microfluidic collection device and qPCR assay. Transl Oncol. 2013;6(5):528–38.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013;5(179):179ra47. doi: 10.1126/scitranslmed.3005616.
  21. 21.
    Riahi R, Gogoi P, Sepehri S, Zhou Y, Handique K, Godsey J, et al. A novel microchannel-based device to capture and analyze circulating tumor cells (CTCs) of breast cancer. Int J Oncol. 2014;44(6):1870–8. doi: 10.3892/ijo.2014.2353.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Hou HW, Warkiani ME, Khoo BL, Li ZR, Soo RA, Tan DS, et al. Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep. 2013;3:1259. doi: 10.1038/srep01259.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Saucedo-Zeni N, Mewes S, Niestroj R, Gasiorowski L, Murawa D, Nowaczyk P, et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol. 2012;41(4):1241–50. doi: 10.3892/ijo.2012.1557.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Wang H, Yue G, Dong C, Wu F, Wei J, Yang Y, et al. Carboxybetaine methacrylate-modified nylon surface for circulating tumor cell capture. ACS Appl Mater Interfaces. 2014;6(6):4550–9. doi: 10.1021/am500394j.CrossRefPubMedGoogle Scholar
  25. 25.
    Lu J, Fan T, Zhao Q, Zeng W, Zaslavsky E, Chen JJ, et al. Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer. 2010;126(3):669–83. doi: 10.1002/ijc.24814.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Hausen BM. Hydrangenol, a strong contact sensitizer found in hydrangea (Hydrangea sp.; Hydrangeaceae). Contact Dermatitis. 1991;24(3):233–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res. 2012;14(1):R15. doi: 10.1186/bcr3099.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Strati A, Kasimir-Bauer S, Markou A, Parisi C, Lianidou ES. Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer. Breast Cancer Res. 2013;15(2):R20. doi: 10.1186/bcr3395.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Stathopoulou A, Gizi A, Perraki M, Apostolaki S, Malamos N, Mavroudis D, et al. Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. Clin Cancer Res. 2003;9(14):5145–51.PubMedGoogle Scholar
  30. 30.
    Alix-Panabieres C, Vendrell JP, Pelle O, Rebillard X, Riethdorf S, Muller V, et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem. 2007;53(3):537–9. doi: 10.1373/clinchem.2006.079509.CrossRefPubMedGoogle Scholar
  31. 31.
    Alix-Panabieres C. EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. Recent Results Cancer Res. 2012;195:69–76. doi: 10.1007/978-3-642-28160-0_6.
  32. 32.
    Pachmann K, Camara O, Kavallaris A, Krauspe S, Malarski N, Gajda M, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(8):1208–15. doi: 10.1200/JCO.2007.13.6523.CrossRefGoogle Scholar
  33. 33.
    Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(7):1420–30. doi: 10.1200/JCO.2005.08.140.CrossRefGoogle Scholar
  34. 34.
    Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(19):3213–21. doi: 10.1200/JCO.2007.15.8923.CrossRefGoogle Scholar
  35. 35.
    Fusi A, Metcalf R, Krebs M, Dive C, Blackhall F. Clinical utility of circulating tumour cell detection in non-small-cell lung cancer. Curr Treat Options Oncol. 2013;14(4):610–22. doi: 10.1007/s11864-013-0253-5.CrossRefPubMedGoogle Scholar
  36. 36.
    Hoshimoto S, Faries MB, Morton DL, Shingai T, Kuo C, Wang HJ, et al. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg. 2012;255(2):357–62. doi: 10.1097/SLA.0b013e3182380f56.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Hofman V, Ilie M, Long E, Guibert N, Selva E, Washetine K, et al. Detection of circulating tumor cells from lung cancer patients in the era of targeted therapy: promises, drawbacks and pitfalls. Curr Mol Med. 2014;14(4):440–56.CrossRefPubMedGoogle Scholar
  38. 38.
    Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013;31(6):539–44. doi: 10.1038/nbt.2576.CrossRefPubMedGoogle Scholar
  39. 39.
    Zhang L, Ridgway LD, Wetzel MD, Ngo J, Yin W, Kumar D, et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med. 2013;5(180):180ra48. doi: 10.1126/scitranslmed.3005109.CrossRefPubMedGoogle Scholar
  40. 40.
    Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014;345(6193):216–20. doi: 10.1126/science.1253533.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Zhang Z, Shiratsuchi H, Lin J, Chen G, Reddy RM, Azizi E, et al. Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget. 2014;5(23):12383–97. doi: 10.18632/oncotarget.2592.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F, et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med. 2014;20(8):897–903. doi: 10.1038/nm.3600.CrossRefPubMedGoogle Scholar
  43. 43.
    Cayrefourcq L, Mazard T, Joosse S, Solassol J, Ramos J, Assenat E, et al. Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res. 2015;75(5):892–901. doi: 10.1158/0008-5472.CAN-14-2613.CrossRefPubMedGoogle Scholar
  44. 44.
    Okabe H, Tsunoda S, Hosogi H, Hisamori S, Tanaka E, Tanaka S, et al. Circulating tumor cells as an independent predictor of survival in advanced gastric cancer. Ann Surg Oncol. 2015;22(12):3954–61. doi: 10.1245/s10434-015-4483-6.CrossRefPubMedGoogle Scholar
  45. 45.
    Lee SJ, Lee J, Kim ST, Park SH, Park JO, Park YS, et al. Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer. Int J Biol Markers. 2015;30(4):e382–6. doi: 10.5301/jbm.5000151.CrossRefPubMedGoogle Scholar
  46. 46.
    Kolostova K, Matkowski R, Gurlich R, Grabowski K, Soter K, Lischke R, et al. Detection and cultivation of circulating tumor cells in gastric cancer. Cytotechnology. 2015; doi: 10.1007/s10616-015-9866-9.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Toyoshima K, Hayashi A, Kashiwagi M, Hayashi N, Iwatsuki M, Ishimoto T, et al. Analysis of circulating tumor cells derived from advanced gastric cancer. Int J Cancer. 2015;137(4):991–8. doi: 10.1002/ijc.29455.CrossRefPubMedGoogle Scholar
  48. 48.
    Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158(5):1110–22.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Ting DT, Wittner BS, Ligorio M, Vincent Jordan N, Shah AM, Miyamoto DT, et al. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep. 2014;8(6):1905–18.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Ge F, Zhang H, Wang DD, Li L, Lin PP. Enhanced detection and comprehensive in situ phenotypic characterization of circulating and disseminated heteroploid epithelial and glioma tumor cells. Oncotarget. 2015;6(29):27049–64.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Li Y, Zhang X, Ge S, Gao J, Gong J, Lu M, et al. Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer. Oncotarget. 2014;5(16):6594–602.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res. 2010;16(9):2634–45.CrossRefPubMedGoogle Scholar
  53. 53.
    Mohamed Suhaimi NA, Foong YM, Lee DY, Phyo WM, Cima I, Lee EX, et al. Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. Mol Oncol. 2015;9(4):850–60.CrossRefPubMedGoogle Scholar
  54. 54.
    Reid AL, Freeman JB, Millward M, Ziman M, Gray ES. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clin Biochem. 2015;48(15):999–1002.CrossRefPubMedGoogle Scholar
  55. 55.
    Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L, et al. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol Oncol. 2015;9(4):749–57.CrossRefPubMedGoogle Scholar
  56. 56.
    Markou A, Farkona S, Schiza C, Efstathiou T, Kounelis S, Malamos N, et al. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer. Clin Cancer Res. 2014;20(22):5823–34.CrossRefPubMedGoogle Scholar
  57. 57.
    Mostert B, Sieuwerts AM, Bolt-de Vries J, Kraan J, Lalmahomed Z, van Galen A, et al. mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients. Mol Oncol. 2015;9(4):920–32.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2017

Authors and Affiliations

  1. 1.The Comprehensive Cancer Centre of Drum Tower HospitalMedical School of Nanjing University and Clinical Cancer Institute of Nanjing UniversityNanjingChina

Personalised recommendations